US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

28.97

-1.1550-3.83%

Volume:147.91K

Turnover:4.39M

Market Cap:1.38B

PE:-10.66

High:30.69

Open:30.19

Low:28.86

Close:30.12

52wk High:42.27

52wk Low:6.43

Shares:47.66M

Float Shares:26.57M

Volume Ratio:0.61

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.7168

EPS(LYR):-3.7760

ROE:-23.41%

ROA:-15.89%

PB:2.70

PE(LYR):-7.67

Loading ...

Overview Company News Filings

Rapport Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Rapport Therapeutics Price Target Maintained With a $47.00/Share by BTIG

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Rapport Therapeutics (RAPP) Valuation After Key Phase 2a Epilepsy Data Presentation Announcement

Simply Wall St.

Can Rapport Therapeutics’ (RAPP) RAP-219 Data Details Reframe Its Neurology Pipeline Valuation?

Simply Wall St.

Rapport Therapeutics COO Cheryl Gault Reports Disposal of Common Shares

Rapport Therapeutics Unveils Positive Phase 2a RAP-219 Data for Focal Onset Seizures

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet

BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target

MT Newswires Live

BUZZ-BTIG turns bullish on biotech sector, sees 2026 as 'banner year'

Rapport Therapeutics Initiated at Buy by BTIG

U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron Technology

Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares

Does Rapport Therapeutics' Rising Losses and Improving Per-Share Results Reveal a Shift in RAPP's Strategy?

Simply Wall St.

H.C. Wainwright Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

H.C. Wainwright Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

Biotech stocks are coming back. Here's what's driving the sector higher.

Buy Rating for Rapport Therapeutics: Promising RAP-219 Results and Strong Financial Position

Rapport Therapeutics Is Maintained at Market Outperform by Citizens

Rapport Therapeutics price target raised to $80 from $77 at Citizens JMP

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAPP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":28.965,"timestamp":1771958191917,"preClose":30.12,"halted":0,"volume":147905,"delay":0,"changeRate":-0.03834661354581677,"floatShares":26567199,"shares":47661138,"eps":-2.716762,"marketStatus":"Trading","change":-1.155,"latestTime":"02-24 13:37:20 EST","open":30.19,"high":30.69,"low":28.86,"amount":4388536.28879,"amplitude":0.060757,"askPrice":29.17,"askSize":122,"bidPrice":28.85,"bidSize":117,"shortable":3,"etf":0,"ttmEps":-2.716762,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":30.12,"postHourTrading":{"tag":"盘后","latestPrice":30.19,"preClose":30.12,"latestTime":"19:54 EST","volume":12461,"amount":380651.05,"timestamp":1771894483039,"change":0.07,"changeRate":0.002324,"amplitude":0.029216},"volumeRatio":0.608577,"impliedVol":1.002,"impliedVolPercentile":0.7012},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":26567199,"roa":"-15.89%","roe":"-23.41%","lyrEps":-3.775953,"volumeRatio":0.608577,"shares":47661138,"dividePrice":0,"high":30.69,"amplitude":0.060757,"preClose":30.12,"low":28.86,"week52Low":6.43,"pbRate":"2.70","week52High":42.2685,"institutionHeld":0,"latestPrice":28.965,"committee":-0.020921,"eps":-2.716762,"divideRate":0,"volume":147905,"delay":0,"ttmEps":-2.716762,"open":30.19,"prevYearClose":30.34,"prevWeekClose":29.76,"prevMonthClose":26.61,"prevQuarterClose":30.34,"fiveDayClose":29.06,"twentyDayClose":26.45,"sixtyDayClose":28.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"RAPP","fiscalQuarterEnding":"2025/09","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1770786000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2026-02-23","current":-11.086728,"percent":0.153846,"low":-19.654107,"twenty":-14.160292,"median":-11.461087,"eighty":-5.664606,"high":-3.640031,"avg":-10.430477,"sd":4.090911,"marketCap":1418395466},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-12","current":-9.588184,"twenty":-13.020376,"median":-8.364435,"eighty":-5.143059,"marketCap":846751744},{"date":"2025-09-19","current":-14.281097,"twenty":-13.398113,"median":-8.486618,"eighty":-5.165131,"marketCap":1261192245},{"date":"2025-09-26","current":-13.038354,"twenty":-13.650327,"median":-8.934622,"eighty":-5.176938,"marketCap":1151443158},{"date":"2025-10-03","current":-14.902468,"twenty":-13.718742,"median":-9.051713,"eighty":-5.195691,"marketCap":1316066789},{"date":"2025-10-10","current":-13.962579,"twenty":-13.896787,"median":-9.158623,"eighty":-5.223161,"marketCap":1233063277},{"date":"2025-10-17","current":-12.986138,"twenty":-13.856058,"median":-9.228454,"eighty":-5.262092,"marketCap":1146831851},{"date":"2025-10-24","current":-13.675391,"twenty":-13.856058,"median":-9.397898,"eighty":-5.294604,"marketCap":1207701093},{"date":"2025-10-31","current":-14.035682,"twenty":-13.934383,"median":-9.502263,"eighty":-5.303959,"marketCap":1239519106},{"date":"2025-11-07","current":-11.969573,"twenty":-13.970933,"median":-9.588184,"eighty":-5.319746,"marketCap":1169427252},{"date":"2025-11-14","current":-12.034803,"twenty":-13.934383,"median":-9.698265,"eighty":-5.33408,"marketCap":1175800274},{"date":"2025-11-21","current":-13.098276,"twenty":-13.915585,"median":-9.917175,"eighty":-5.342242,"marketCap":1279701555},{"date":"2025-11-28","current":-14.493474,"twenty":-13.931568,"median":-10.309179,"eighty":-5.356195,"marketCap":1416012409},{"date":"2025-12-05","current":-14.000764,"twenty":-13.954437,"median":-10.426271,"eighty":-5.376155,"marketCap":1367874660},{"date":"2025-12-12","current":-14.039791,"twenty":-13.99491,"median":-10.604143,"eighty":-5.393122,"marketCap":1371687551},{"date":"2025-12-19","current":-14.459326,"twenty":-14.050476,"median":-10.719003,"eighty":-5.431972,"marketCap":1412676130},{"date":"2025-12-26","current":-15.088628,"twenty":-14.119227,"median":-10.841851,"eighty":-5.476848,"marketCap":1474158998},{"date":"2026-01-02","current":-14.800808,"twenty":-14.281097,"median":-10.940782,"eighty":-5.513507,"marketCap":1446038926},{"date":"2026-01-09","current":-13.81051,"twenty":-14.281097,"median":-10.976093,"eighty":-5.513507,"marketCap":1349286816},{"date":"2026-01-16","current":-13.103154,"twenty":-14.237527,"median":-11.048158,"eighty":-5.513507,"marketCap":1280178166},{"date":"2026-01-23","current":-13.620256,"twenty":-14.172521,"median":-11.156822,"eighty":-5.535473,"marketCap":1330698972},{"date":"2026-01-30","current":-13.049493,"twenty":-14.13499,"median":-11.312246,"eighty":-5.592253,"marketCap":1274935441},{"date":"2026-02-06","current":-12.464095,"twenty":-14.128014,"median":-11.370643,"eighty":-5.617345,"marketCap":1217742075},{"date":"2026-02-13","current":-13.644647,"twenty":-14.087483,"median":-11.410917,"eighty":-5.641114,"marketCap":1333082029},{"date":"2026-02-20","current":-14.630067,"twenty":-14.14031,"median":-11.45735,"eighty":-5.660027,"marketCap":1429357528},{"date":"2026-02-23","current":-14.517866,"twenty":-14.160292,"median":-11.461087,"eighty":-5.664606,"marketCap":1418395466}],"updateTime":1771932236845},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590326824","title":"Rapport Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590326824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590326824?lang=en_us&edition=fundamental","pubTime":"2025-12-10 02:33","pubTimestamp":1765305180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 13:33 ET (18:33 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2589333450","title":"Rapport Therapeutics Price Target Maintained With a $47.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2589333450","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589333450?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:56","pubTimestamp":1765191360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 05:56 ET (10:56 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2589818643","title":"Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818643","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818643?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943200,"startTime":"0","endTime":"0","summary":"Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200745/0/en/Rapport-Therapeutics-Announces-New-Data-and-Post-Hoc-Analysis-Demonstrating-the-Magnitude-and-Consistency-of-RAP-219-s-Clinical-Response-in-Patients-with-Focal-Onset-Seizures.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","POST"],"gpt_icon":0},{"id":"2589536890","title":"Rapport Therapeutics (RAPP) Valuation After Key Phase 2a Epilepsy Data Presentation Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2589536890","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589536890?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:21","pubTimestamp":1764937263,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) is stepping into a key spotlight, with plans to unveil detailed Phase 2a data for its lead epilepsy candidate RAP-219 at the 2025 American Epilepsy Society meeting in Atlanta.\nSee our latest analysis for Rapport Therapeutics.\nThe upcoming AES presentation lands after a powerful run, with the share price at $28.70 and a 90 day share price return of nearly 100 percent, suggesting momentum has been building as investors reassess RAP 219’s potential.\nIf this kind of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/rapport-therapeutics-rapp-valuation-after-key-phase-2a-epile","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/rapport-therapeutics-rapp-valuation-after-key-phase-2a-epile","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2588504070","title":"Can Rapport Therapeutics’ (RAPP) RAP-219 Data Details Reframe Its Neurology Pipeline Valuation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588504070","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588504070?lang=en_us&edition=fundamental","pubTime":"2025-12-04 11:26","pubTimestamp":1764818811,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics announced that it will present detailed Phase 2a data for its lead candidate RAP-219 in focal onset seizures, including efficacy and safety outcomes, at the American Epilepsy Society Annual Meeting in Atlanta on December 5–9, 2025.\nA particularly interesting angle for investors is the planned disclosure of how RAP-219’s efficacy varies over the first month of treatment and across different baseline disease severities, offering a deeper look at its potential clinical...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/can-rapport-therapeutics-rapp-rap-219-data-details-reframe-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/can-rapport-therapeutics-rapp-rap-219-data-details-reframe-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2588703558","title":"Rapport Therapeutics COO Cheryl Gault Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703558","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588703558?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:18","pubTimestamp":1764623895,"startTime":"0","endTime":"0","summary":"Cheryl Gault, Chief Operating Officer of Rapport Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3CBvSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics COO Cheryl Gault Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2586090427","title":"Rapport Therapeutics Unveils Positive Phase 2a RAP-219 Data for Focal Onset Seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2586090427","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586090427?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:00","pubTimestamp":1764072021,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company, announced that it will present new data from its Phase 2a trial of RAP-219 in focal onset seizures at the upcoming 2025 American Epilepsy Society  Annual Meeting, scheduled for December 5-9, 2025, in Atlanta. The presentations will include analyses of RAP-219's effect during the first month of treatment, consistency of efficacy over the treatment period, effectiveness across varying baseline disease severities, and impact on seizure severity. Both topline efficacy and safety data, as well as additional exploratory analyses, will be shared during poster sessions and a dedicated Scientific Exhibit Room at the meeting. The results have not yet been presented and will be made available during the AES conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL29PJXn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","NDAQ","RAPP","BK4007","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2584920227","title":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2584920227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584920227?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:59","pubTimestamp":1763578756,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, AlphabetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV0MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIOT","FCX","GLBE","ACHR","LZB","CSIQ","PLUG","NEM","VTVT","OWL","GEV","ONCY","SCCO","NNOX","VVV","TGT","XOM","DY","WDC","RDW","AGIO","NVDA","OKLO","GOOGL","OXY","KZIA","CDE","STX","NNE","DOW","COIN","COP","GLAD","ALZN","SION","ON","CVX","H","MSTR","OLMA","RAPP","SHBI","PRAX","NUVL","CEVA","ZION","SNDK","LOW","DLB","PPL"],"gpt_icon":0},{"id":"2584494624","title":"BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2584494624","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584494624?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:38","pubTimestamp":1763555917,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) has an average rating of Buy and mean price target of $51.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAPP"],"gpt_icon":0},{"id":"2584494889","title":"BUZZ-BTIG turns bullish on biotech sector, sees 2026 as 'banner year'","url":"https://stock-news.laohu8.com/highlight/detail?id=2584494889","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584494889?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:02","pubTimestamp":1763550134,"startTime":"0","endTime":"0","summary":"BUZZ-BTIG turns bullish on biotech sector, sees 2026 as 'banner year'** With eased interest rates and an uptick in M&A, BTIG says sentiment has been positive for small and mid-cap biotech stocks in 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV0JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VTVT","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","RAPP","SION","BK4139","PRAX"],"gpt_icon":0},{"id":"2584171289","title":"Rapport Therapeutics Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2584171289","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584171289?lang=en_us&edition=fundamental","pubTime":"2025-11-19 18:21","pubTimestamp":1763547660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 05:21 ET (10:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2584463918","title":"U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2584463918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584463918?lang=en_us&edition=fundamental","pubTime":"2025-11-19 15:17","pubTimestamp":1763536636,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron TechnologyNov 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","KNTK","RAPP","LU2039709279.SGD","LU2498475776.HKD","ZION","LGIH","MU","HD","NUVB","ENR","SG9999015358.SGD","PCVX","FCX","VTVT","LU0266013472.USD","LU0289739699.SGD","LU2756315664.SGD","CRWD","LU0820561818.USD","LU0127658192.USD","MBI","AMGN","DKS","DASH","89888","OLMA","LU1585245621.USD","ARWR","ZYME","TERN","BK4549","IPAR","WCC","LU0353189763.USD","BK4548","LU0079474960.USD","LU2065170008.USD","SION","RARE","BK1609","COTY","BRBR","SG9999014542.SGD","INCY","UHS"],"gpt_icon":1},{"id":"2584966329","title":"Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584966329","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584966329?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:25","pubTimestamp":1763501117,"startTime":"0","endTime":"0","summary":"David Bredt, Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL7bFfkN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics Chief Scientific Officer David Bredt Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2584604646","title":"Does Rapport Therapeutics' Rising Losses and Improving Per-Share Results Reveal a Shift in RAPP's Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584604646","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584604646?lang=en_us&edition=fundamental","pubTime":"2025-11-18 07:17","pubTimestamp":1763421463,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics recently reported third-quarter 2025 earnings, disclosing a net loss of US$26.93 million, which was larger than its loss for the same quarter last year.\nWhile quarterly losses widened, the nine-month basic loss per share improved to US$2.15 compared to US$3.66 for the same period a year ago.\nWe'll explore how the company's expanding quarterly losses shape the current investment narrative for Rapport Therapeutics going forward.\nFind companies with promising cash flow...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/does-rapport-therapeutics-rising-losses-and-improving-per-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/does-rapport-therapeutics-rising-losses-and-improving-per-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2583568006","title":"H.C. Wainwright Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583568006","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583568006?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:38","pubTimestamp":1763163535,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Rapport Therapeutics, Inc., with a price target of $34.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2582800817","title":"H.C. Wainwright Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800817","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800817?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:15","pubTimestamp":1762737358,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Rapport Therapeutics, Inc. yesterday and set a price target of $34.00. Tsao covers ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2582865291","title":"Biotech stocks are coming back. Here's what's driving the sector higher.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582865291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582865291?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:57","pubTimestamp":1762621020,"startTime":"0","endTime":"0","summary":"The volatile sector is seeing greater stability, and these four stocks can profit. Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 percentage points.Biotech's strength is likely to continue - so it's not too late for investors to get in, sector analysts say.\"Biotech will be a comparative outperformer,\" says Motley Fool biotech analyst Karl Thiel. \"There is better sentiment and fund-flow, and that feeds on itself. That can unravel quickly but I still think it has some legs.\". Stifel's head of biotech research, Paul Matteis, agrees. \"The sector's run has been driven by a number of credible fundamental factors that seem mostly sustainable,\" he said in a recent interview.M&A also puts higher valuations on biotech companies in general because investors start considering how much more profitable potential drugs might be in the hands of companies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985481810.HKD","LU1623119135.USD","LU2242646821.SGD","QURE","SGXZ81514606.USD","ARGX","LU1894683264.USD","LU2237443622.USD","LU1839511570.USD","LU2168563687.JPY","LU0321505439.SGD","ALKS","MBX","PRAX","AMGN","LU2129689514.USD","SG9999002232.USD","LU0545039389.USD","BMY","LU0689626769.HKD","BK4548","LU2237443549.SGD","LU2360106947.USD","NBIX","IE00BGHQF631.EUR","LU2237443978.SGD","SG9999001440.SGD","ASND","LU0786609619.USD","LU2237443382.USD","LU0471298694.HKD","ABBV","IE00B19Z3B42.SGD","ALNY","RAPP","LU0553294199.USD","BK4559","BK4585","LU2552382058.USD","LU2106854487.HKD","BBIO","LU1093756325.SGD","LU0097036916.USD","MDGL","SG9999014906.USD","LU1267930490.SGD","LU1366192091.USD","LU0965509101.SGD"],"gpt_icon":1},{"id":"2581783537","title":"Buy Rating for Rapport Therapeutics: Promising RAP-219 Results and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2581783537","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581783537?lang=en_us&edition=fundamental","pubTime":"2025-11-08 02:55","pubTimestamp":1762541733,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh has reiterated their bullish stance on RAPP stock, giving a Buy rating today. Justin Walsh has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-rapport-therapeutics-promising-rap-219-results-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-rapport-therapeutics-promising-rap-219-results-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2581889553","title":"Rapport Therapeutics Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581889553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581889553?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:25","pubTimestamp":1762525500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 09:25 ET (14:25 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2581009530","title":"Rapport Therapeutics price target raised to $80 from $77 at Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009530?lang=en_us&edition=fundamental","pubTime":"2025-11-07 18:50","pubTimestamp":1762512653,"startTime":"0","endTime":"0","summary":"Citizens JMP raised the firm’s price target on Rapport Therapeutics (RAPP) to $80 from $77 and keeps an Outperform rating on the shares. Rapport re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-price-target-raised-to-80-from-77-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-price-target-raised-to-80-from-77-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","JMP"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":101,"code":"91000000","status":"200"}]}}